ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $84.96, for a total value of $50,976.00. Following the transaction, the insider now owns 62,602 shares of the company’s stock, valued at approximately $5,318,665.92. The transaction was disclosed in a filing with the SEC, which is available at this link.

James Hollingshead also recently made the following trade(s):

  • On Monday, November 20th, James Hollingshead sold 7,019 shares of ResMed stock. The stock was sold at an average price of $84.16, for a total value of $590,719.04.

ResMed Inc. (NYSE RMD) opened at $87.69 on Friday. The stock has a market capitalization of $12,280.36, a PE ratio of 30.15, a price-to-earnings-growth ratio of 1.90 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72. ResMed Inc. has a 1-year low of $61.63 and a 1-year high of $87.81.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.66. The company had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. ResMed’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. equities analysts forecast that ResMed Inc. will post 3.04 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th were issued a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend was Wednesday, November 8th. ResMed’s payout ratio is 56.68%.

A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a report on Friday. Northland Securities reiterated a “sell” rating and set a $55.00 target price on shares of ResMed in a report on Friday, October 27th. Jefferies Group reiterated a “sell” rating and set a $56.00 target price on shares of ResMed in a report on Thursday, October 12th. BMO Capital Markets increased their target price on ResMed to $82.00 and gave the stock a “market perform” rating in a report on Tuesday, December 12th. Finally, Barclays increased their target price on ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a report on Monday, September 25th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. ResMed currently has a consensus rating of “Hold” and a consensus price target of $68.71.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of ResMed by 6.8% in the 2nd quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock valued at $1,108,877,000 after acquiring an additional 904,939 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of ResMed by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock valued at $927,797,000 after acquiring an additional 378,964 shares in the last quarter. FMR LLC grew its holdings in shares of ResMed by 38.2% in the 2nd quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after acquiring an additional 1,531,772 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of ResMed by 0.9% in the 3rd quarter. Baillie Gifford & Co. now owns 4,913,626 shares of the medical equipment provider’s stock valued at $378,154,000 after acquiring an additional 44,340 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of ResMed by 8.7% in the 2nd quarter. Northern Trust Corp now owns 1,473,925 shares of the medical equipment provider’s stock valued at $114,774,000 after acquiring an additional 118,428 shares in the last quarter. Institutional investors own 61.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/james-hollingshead-sells-600-shares-of-resmed-inc-rmd-stock/1797232.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with Analyst Ratings Network's FREE daily email newsletter.